Literature DB >> 3343017

Effect of single and repeated intravenous doses of omeprazole on pentagastrin stimulated gastric acid secretion and pharmacokinetics in man.

J B Jansen1, P Lundborg, L C Baak, J Greve, M Ohman, C Stöver, K Röhss, C B Lamers.   

Abstract

Single intravenous doses of 10, 20, 40, and 80 mg and repeated once daily intravenous doses of 10 and 20 mg omeprazole induced a powerful and long lasting inhibition of pentagastrin stimulated gastric acid secretion (PAO) in healthy male volunteers. Single intravenous doses of 10, 20, 40, and 80 mg omeprazole inhibited PAO by 30% (p less than 0.01), 45% (p less than 0.01), 61% (p less than 0.01), and 80% (p less than 0.01), respectively when measured 1.5 h after dose, and by 20% (NS), 27% (NS), 36% (p less than 0.01) and 59% (p less than 0.01), respectively when measured 24 h after dose. Six days after repeated once daily intravenous doses of 10 and 20 mg omeprazole, PAO was inhibited by 63% (p less than 0.01) and 82% (p less than 0.01), respectively when measured 1.5 h after dose, and by 32% (p less than 0.01) and 43% (p less than 0.01), respectively when measured 24 h after dose. The inhibition of PAO by 10 mg administered intravenously as a single bolus injection was comparable with the inhibition by 20 mg as a single oral dose. Repeated once daily administration of 10 mg intravenously and 20 mg orally also resulted in comparable reductions in PAO. The reduction in PAO after repeated once daily oral administration of 20 mg was comparable with the effect of a single intravenous dose of 40 mg. Terminal half lives were short, but significantly (p less than 0.05) prolonged after a single intravenous injection of 80 mg. Repeated once daily intravenous administration of 10 and 20 mg did not result in prolongation of terminal half lives. It is concluded that intravenous administration of omeprazole causes a potent and long acting inhibition of pentagastrin stimulated gastric acid secretion in man. Its potency is augmented after repeated once daily administration.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3343017      PMCID: PMC1433269          DOI: 10.1136/gut.29.1.75

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  13 in total

1.  Effect of omeprazole and cimetidine on duodenal ulcer. A double-blind comparative trial.

Authors:  K Lauritsen; S J Rune; P Bytzer; H Kelbaek; K G Jensen; J Rask-Madsen; F Bendtsen; J Linde; M Højlund; H H Andersen
Journal:  N Engl J Med       Date:  1985-04-11       Impact factor: 91.245

2.  Effects of single and repeated doses of omeprazole on gastric acid and pepsin secretion in man.

Authors:  C W Howden; J A Forrest; J L Reid
Journal:  Gut       Date:  1984-07       Impact factor: 23.059

3.  Omeprazole: effective, convenient therapy for Zollinger-Ellison syndrome.

Authors:  K E McArthur; M J Collen; P N Maton; J A Cherner; J M Howard; C A Ciarleglio; M J Cornelius; R T Jensen; J D Gardner
Journal:  Gastroenterology       Date:  1985-04       Impact factor: 22.682

4.  Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+)ATPase.

Authors:  E Fellenius; T Berglindh; G Sachs; L Olbe; B Elander; S E Sjöstrand; B Wallmark
Journal:  Nature       Date:  1981-03-12       Impact factor: 49.962

5.  Omeprazole in Zollinger-Ellison syndrome. Effects of a single dose and of long-term treatment in patients resistant to histamine H2-receptor antagonists.

Authors:  C B Lambers; T Lind; S Moberg; J B Jansen; L Olbe
Journal:  N Engl J Med       Date:  1984-03-22       Impact factor: 91.245

6.  Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis.

Authors:  E C Klinkenberg-Knol; J M Jansen; H P Festen; S G Meuwissen; C B Lamers
Journal:  Lancet       Date:  1987-02-14       Impact factor: 79.321

7.  Determination of omeprazole and metabolites in plasma and urine by liquid chromatography.

Authors:  P O Lagerström; B A Persson
Journal:  J Chromatogr       Date:  1984-08-10

8.  Rapid healing of duodenal ulcers with omeprazole: double-blind dose-comparative trial.

Authors:  S Gustavsson; H O Adami; L Lööf; A Nyberg; O Nyrén
Journal:  Lancet       Date:  1983-07-16       Impact factor: 79.321

9.  Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man.

Authors:  T Lind; C Cederberg; G Ekenved; U Haglund; L Olbe
Journal:  Gut       Date:  1983-04       Impact factor: 23.059

10.  [Behavior of acid secretion under the long-term daily administration of omeprazol].

Authors:  H G Dammann; P Müller; H K Seitz; B Simon
Journal:  Schweiz Med Wochenschr       Date:  1983-06-18
View more
  19 in total

1.  Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole.

Authors:  Z Hussein; G R Granneman; D Mukherjee; E Samara; D L Hogan; M A Koss; J I Isenberg
Journal:  Br J Clin Pharmacol       Date:  1993-11       Impact factor: 4.335

2.  Early effects of oral administration of omeprazole and roxatidine on intragastric pH.

Authors:  Hiroshi Iida; Shingo Kato; Yusuke Sekino; Eiji Sakai; Takashi Uchiyama; Hiroki Endo; Kunihiro Hosono; Yasunari Sakamoto; Koji Fujita; Masato Yoneda; Tomoko Koide; Hirokazu Takahashi; Chikako Tokoro; Ayumu Goto; Yasunobu Abe; Noritoshi Kobayashi; Kensuke Kubota; Eiji Gotoh; Shin Maeda; Atsushi Nakajima; Masahiko Inamori
Journal:  J Zhejiang Univ Sci B       Date:  2012-01       Impact factor: 3.066

3.  Effect of short-term omeprazole administration on serum pepsinogens in relation to fasting serum gastrin and gastric acid secretion.

Authors:  I Biemond; L F Crobach; J B Jansen; C B Lamers
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Effect of intravenous omeprazole on intragastric pH during intravenous infusion of amino acids.

Authors:  L C Baak; J B Jansen; C B Lamers
Journal:  Dig Dis Sci       Date:  1990-05       Impact factor: 3.199

Review 5.  Effects of preoperative proton pump inhibitor administration on bleeding after gastric endoscopic submucosal dissection: A systematic review and meta-analysis.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Teppei Akimoto; Tadateru Maehata; Toshio Morizane; Takanori Kanai; Naohisa Yahagi
Journal:  United European Gastroenterol J       Date:  2015-06-09       Impact factor: 4.623

6.  Stress-related Mucosal Disease.

Authors:  Mitchell J. Spirt
Journal:  Curr Treat Options Gastroenterol       Date:  2003-04

7.  Preprocedural rabeprazole treatment before endoscopic submucosal dissection for gastric neoplasms.

Authors:  Myong Ki Baeg; Myung-Gyu Choi; Seong Jin Moon; Chul-Hyun Lim; Jin Su Kim; Yu Kyung Cho; Jae Myung Park; In Seok Lee; Sang Woo Kim; Kyu Yong Choi
Journal:  Dig Dis Sci       Date:  2014-03-27       Impact factor: 3.199

8.  Individual and group dose-responses to intravenous omeprazole in the first 24 h: pH-feedback-controlled and fixed-dose infusions.

Authors:  C H Wilder-Smith; H U Bettschen; H S Merki
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

Review 9.  Optimal treatment of Zollinger-Ellison syndrome and related conditions in elderly patients.

Authors:  Paola Tomassetti; Teresa Salomone; Marina Migliori; Davide Campana; Roberto Corinaldesi
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

10.  Antagonism of Fluconazole and a Proton Pump Inhibitor against Candida albicans.

Authors:  Ning-Ning Liu; Julia R Köhler
Journal:  Antimicrob Agents Chemother       Date:  2015-11-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.